|

Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.

RECRUITINGSponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Actively Recruiting
SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Started2026-05-26
Est. completion2027-02-25
Eligibility
Age20 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07652892

Summary

The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.

Eligibility

Age: 20 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients will be included who are able to provide informed consent and actively participate in periodic assessments.

Exclusion Criteria:

* Risky alcohol consumption:

\> 30 g/day in men and \> 20 g/day in women. AUDIT score: \> 7 points in men, \> 5 in women.

* Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.).
* Advanced neurodegenerative diseases or severe psychiatric disorders.
* Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.

Conditions2

Liver DiseaseSteatosis of Liver

Browse More Trials

Liver Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.